Price close 16 Nov 2026
- 1M
- +1.5%
- 6M
- +26.2%
- YTD
- +24.8%
- 1Y
- +28.2%
- 3Y
- +78.4%
- 10Y
- +122%
Price change over each period, from daily closes; dividends not included.
Price change over each period, from daily closes; dividends not included.
iShares Biotechnology ETF (IBB) is a health care sector equity exchange-traded fund from BlackRock, tracking the NYSE Biotechnology Index Spliced.
It holds 248 positions, the ten largest 51.5% of the fund.
Its net assets were $11.0 billion on November 13, 2026; it is the 3rd largest of the 4 health care funds among the 300 largest ETFs.
From the fund's prospectus and its latest holdings (13 Nov 2026), compiled and checked by AapWire.
| Holding | Weight | Weight bar |
|---|---|---|
| Gilead Sciences GILD | 9.01% | |
| Amgen Inc AMGN | 8.50% | |
| Vertex Pharmaceuticals VRTX | 7.76% | |
| Regeneron Pharmaceuticals REGN | 6.58% | |
| Moderna MRNA | 5.67% | |
| Argenx Se Adr ARGX | 3.70% | |
| Natera NTRA | 2.98% | |
| Biogen BIIB | 2.58% | |
| Beone Medicines Ag ONC | 2.43% | |
| Revolution Medicines RVMD | 2.31% |
| Health Care | 100.0% |
|---|
The eleven sectors of the company pages: an S&P 500 member counts in its index sector, any other holding in its industry's; shares of the stock that has a sector.
Countries as the fund reports them: US 89.5%, BE 3.8%, CN 2.8%, DK 2.0%, DE 0.6%, FR 0.4%.
| Category | Health care · Sector equity |
|---|---|
| Issuer | BlackRock |
| Index | NYSE Biotechnology Index Spliced |
| Expense ratio | — |
| Net assets | $11.0B · 13 Nov 2026 |
| Holdings | 248 · ten largest 51.5% |
| Legal form | Registered fund |
| Rank in category | 3 of 4 · by size, among the 300 largest ETFs |
IBB tracks the NYSE Biotechnology Index Spliced.
IBB held 248 positions on November 13, 2026.
Gilead Sciences (9.0%), Amgen Inc (8.5%), Vertex Pharmaceuticals (7.8%), Regeneron Pharmaceuticals (6.6%), Moderna (5.7%).
IBB is issued by BlackRock; it is a registered fund.
In the terminal
The fund's costs and returns are read from its prospectus, its positions from its latest report or its issuer's own file, and its category from what it holds and how it names itself. A figure that cannot be read is left blank. See data and methodology.